uniQure (QURE) Announces New Preclinical Data on AMT-130 in Huntington’s Disease
Tweet Send to a Friend
uniQure N.V. (NASDAQ: QURE) today presented new preclinical data on AMT-130, its proprietary gene therapy candidate for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE